Hongbing Ma

Curriculum Vitae

Hongbing Ma M.D., Ph.D. Chief Physician, Professor , Doctoral supervisor

Department of Oncology and Radiotherapy, The Second Affiliated Hospital, Xi 'an Jiaotong University,

157 Xi Wu Road, Xi’an, Shaanxi Province, P .R. China, 710004 T el 86-13991845066

E-mail: mhbxian@126.com

Research area (direction)

1. Mechanisms of concurrent chemoradiotherapy and radiotherapy sensitization

2. Molecular mechanisms of radiotherapy and immunotherapy

Professional experience

professor, chief physician

Academic and professional doctoral supervisor and master supervisor The director of the Department of Oncology and Radiotherapy

The vice president of the Cancer Hospital

The deputy director of the Department of Oncology

A famous teacher of the Medical Department of Xi 'an Jiaotong University

(1) July 1998-present, Department of Oncology and Radiotherapy, The Second Affiliated Hospital,

Xi 'an Jiaotong University, Professor

(2) July 1992 to June 1995, Northwest Simian Hospital, Surgery, Assistant professor

Education

(1) From September 2001 to November 2004, Xi 'an Jiaotong University, Human Anatomy and Histology, ph. D. ，Supervisor: Haitao Hu

(2) from September 1995 to June 1998, Hepatobiliary Surgery, Xi 'an Medical University, Master， supervisor: Zuoren Wang

(3) September 1987 to June 1992, Yan 'an Medical College, Clinical Medicine, Bachelor of Medicine

Professional Activities

Member of radiation Oncologists Branch, Chinese Medical Doctor Association Member of radiation Oncology Professional Committee, Chinese Anti-cancer Society Member of radiological Protection Committee, Chinese Anti-Cancer Association

Member of radiation Oncology Special Committee, Chinese Society of Research Hospitals

Member of esophageal cancer and Pediatric Oncology Group, Radiation Oncology Branch, Chinese Medical Association

Member of lung cancer and Rectal Cancer Group, Tumor Radiotherapy Professional Committee, Chinese Anti-Cancer Association

Member of standing committee of executive Committee of China Oncology Radiotherapy Alliance

Member of the Standing Committee of the North Radiotherapy Cooperation Group Director, Western Society for Radiation Oncology Therapy

Chairman of tumor and Radiotherapy Professional Committee of Shaanxi Health Association

Chairman of tumor Radiation Protection Professional Committee, Shaanxi Anti-cancer Association

Editorial Board of Oncology and Translational Medicine

Research Support

Mechanism of Treg cell activation of FZD7/β-catenin/GPX4 signaling pathway to inhibit tumor iron death and promote radiotherapy resistance of esophageal squamous cell carcinoma(National Natural Science Foundation of China, 82172839, in research)

The role and mechanism of tumor exosome miRNA in regulating Treg cells in radioreactance of esophageal squamous cell carcinoma (National Natural Science Foundation of China, 81872471, in research)

Regulation of tumor microenvironment Treg cells by exosome Mir-155 in esophageal squamous cell carcinoma and its mechanism(Shaanxi Provincial Key RESEARCH and Development Program -- General Project 2021SF-122 in Social Development, under research)

Academic and scientific research achievements, patents, papers

1. Interaction between tumor cells and surrounding interstitial cells during tumor development and its mechanism (Second Prize of Science and Technology Award of Shaanxi Provincial People's Government, 2013)

2. Research on gene targeted therapy and radiation Sensitization of pancreatic cancer (Second Prize of Science and Technology Award of Shaanxi Provincial People's Government, 2014)

3、Liu X, Guo W, Shi X, Ke Y, Li Y, Pan S, Jin Y, Wang Y, Ruan Q, Ma H*. Construction and verification of prognostic nomogram for early-onset esophageal cancer. Bosn J Basic Med Sci. 2021 Mar 22. doi: 10.17305/bjbms.2021.5533.

4 、 Yue Ke;Wei Guo; Shan Huang; Yuxing Li; Yuyan Guo; Xiaoxiao Liu; Yingying Jin; Hongbing Ma*; RYBP inhibits esophageal squamous cell carcinoma proliferation through downregulating CDC6 and CDC45 in G1-S phase transition process, Life Sciences, 2020, June 1;250:117578.

5 、 Ma H,ZhengS,Zhang X,Gong T,LvX,Fu S,Zhang S,Yin X,HaoJ,Shan C,Huang S*.High mobility group box 1 promotes radioresistance in esophageal squamous cell carcinoma cell lines by modulating autophagy.Cell Death Dis. 2019，10(2):136.

6 、 Jin Y,XuK,Chen Q,Wang B,Pan J,Huang S,Wei Y,Ma H*.Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway.Exp Cell Res.2018，362(2):362-369.

7 、 Huixia Peng ; Zhengli Di;Yingying Jin; Yue Ke; Shan Huang; Hongbing Ma*.A phase II study of neoadjuvant radiochemotherapy followed by Surgery for locally advanced cervical cance. Int J Clin Exp Med.2016, 9(12):23454-23460

8 、 Ying-ying Jin ; Qing-juan Chen; Kun Xu; Hong-tao Ren; Xing Bao; Yi-nan Ma; Yang Wei; Hong bing Ma*.Involvement of microRNA-141-3p in 5-uorouracil and oxaliplatin chemo- resistance in esophageal cancer cells via regulation of PTEN. Mol Cell Biochem . 2016.422(1-2): 161-170

9 、 Ying-Ying Jin ; Qing-Juan Chen; Yang Wei; Ya-Li; Zhong-Wei Wang; Kun Xu; Yun He; Hong-Bing Ma*.Upregulation of microRNA-98 increases radiosensitivity in esophageal squamous cell carcinoma, Journal of Radiation Research,2016.7.15, 57(5): 468~476

10、Ma, Hong-Bing* ; Di, Zheng-Li; Wen, Jiao; Ke, Yue; Sun, Xiaodong;Ren, Juan,Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma. Jpn J Clin Oncol, 、 2015.2, 45(2): 169~175

11、Baofeng Wang ; Baohua Li; Zhijun Dai; Song Ren; Minghua Bai; ZhongweiWang; Zongfang Li; Shuai Lin; Zhidong Wang; Na Huang; Pengtao Yang; Mengjie Liu; Weili Min; Hongbing Ma*.Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells. The International Journal of Biochemistry & Cell Biology, 2014.10, 55: 98~108

12、Yin, Xiaoran ; Zhang, Rong; Feng, Cheng; Zhang, Jun; Liu, Dong; Xu,Kun; Wang, Xijing; Zhang, Shuqun; Li, Zongfang; Liu, Xinlian;Diallyl disulfide induces G2/M arrest and promotes apoptosis through the p53/p21 and MEK-ERK pathways in human esophageal squamous cell carcinoma. Oncol Rep, 2014.10, 32(4): 1748~1756

13 、 Ma, Hong-Bing* ; Huang, Shan; Yin, Xiao-Ran; Zhang, Yang; Di,Zheng-Li Apoptotic pathway induced by diallyl trisulfide in pancreatic cancer cells. World J Gastroenterol, 2014.1.7, 20(1): 193~203

14、Yin, Xiaoran ; Zhang, Jun; Li, Xiaoning; Liu, Dong; Feng, Cheng;Liang, Rongrui; Zhuang, Kun; Cai, Chenlei; Xue, Xinghuan; Jing, Fuchun; Wang,Xijing; Wang, Jun; Liu, Xinlian; DADS suppresses human esophageal xenograft tumors through RAF/MEK/ERK and mitochondria- dependent pathways. Int J Mol Sci, 2014, 15(7): 12422~12441